AR002002A1 - USE OF THE EPIDERMIC GROWTH FACTOR IN THE MANUFACTURE OF A MEDICINE IN THE FORM OF HYDROPHILIC CREAM FOR THE TREATMENT OF ACNE. - Google Patents

USE OF THE EPIDERMIC GROWTH FACTOR IN THE MANUFACTURE OF A MEDICINE IN THE FORM OF HYDROPHILIC CREAM FOR THE TREATMENT OF ACNE.

Info

Publication number
AR002002A1
AR002002A1 ARP950100314A AR10031495A AR002002A1 AR 002002 A1 AR002002 A1 AR 002002A1 AR P950100314 A ARP950100314 A AR P950100314A AR 10031495 A AR10031495 A AR 10031495A AR 002002 A1 AR002002 A1 AR 002002A1
Authority
AR
Argentina
Prior art keywords
treatment
acne
egf
medicine
manufacture
Prior art date
Application number
ARP950100314A
Other languages
Spanish (es)
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of AR002002A1 publication Critical patent/AR002002A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/86—Products or compounds obtained by genetic engineering

Abstract

La presente invención está relacionada con la rama de la Medicina y en particular con el empleo del Factor de Crecimiento Epidérmico (EGF) humano yrecombinante en la fabricación de un medicamento para el tratamiento del acné. La composición consiste en una crema hidrófila a base de ácido esteárico comoespesante, carbonato de potasio anhidro como emulsionante y espesante, metilparabeno y propilparabeno como preservativo antimicrobiano, glicerina comohumectante y agua purificada como disolvente y una cantidad de EGF que oscila entre 2 y 50 µg/g, preferiblemente 10 µg/g. Su objetivo técnico es lograr unproducto eficaz para el tratamiento de esta enfermedad crónica de la piel con implicaciones estéticas y psicológicas, demostrándose la utilidad de esteprincipio activo para la fabricación de un medicamento para el tratamiento de dicha patología en un ensayo clínico realizado a doble ciego. De un total de 30pacientes con acné activo tratados diariamente durane 90 días, se determinó el grado de afección según la escala de 8 grados del Colegio Médico UniversitarioInglés, al inicio, a los 45 días y al finalizar el tratamiento. El grupo tratado con EGF presentó mejoría sgnificativa (p<0,01) con respecto al querecibió placebo, encontrándose en el grupo que se utilizó EGF una mejoría general en 23 pacientes (79,3%), destacándose de ellos 15 (51,7%) mucho mejor y8(27,5%) mejor. Ningún paciente empeoró. Esta invención puede emplearse como alternativa terapéutica para el tratamiento del acné crónico.The present invention is related to the branch of Medicine and in particular to the use of the human and recombinant Epidermal Growth Factor (EGF) in the manufacture of a medicine for the treatment of acne. The composition consists of a hydrophilic cream based on stearic acid as a thickener, anhydrous potassium carbonate as an emulsifier and thickener, methylparaben and propylparaben as an antimicrobial preservative, glycerin as a humectant and purified water as a solvent and an amount of EGF ranging from 2 to 50 µg / g, preferably 10 µg / g. Its technical objective is to achieve an effective product for the treatment of this chronic skin disease with aesthetic and psychological implications, demonstrating the usefulness of this active principle for the manufacture of a drug for the treatment of said pathology in a double-blind clinical trial. Out of a total of 30 patients with active acne treated daily for 90 days, the degree of affection was determined according to the 8-degree scale of the English University Medical College, at the beginning, at 45 days and at the end of treatment. The group treated with EGF showed significant improvement (p <0.01) with respect to that received placebo, finding in the group that used EGF a general improvement in 23 patients (79.3%), 15 of them standing out (51.7 %) much better and 8 (27.5%) better. No patient worsened. This invention can be used as a therapeutic alternative for the treatment of chronic acne.

ARP950100314A 1994-11-25 1995-11-24 USE OF THE EPIDERMIC GROWTH FACTOR IN THE MANUFACTURE OF A MEDICINE IN THE FORM OF HYDROPHILIC CREAM FOR THE TREATMENT OF ACNE. AR002002A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1994136A CU22613A1 (en) 1994-11-25 1994-11-25 USE OF EPIDERMIC GROWTH FACTOR FOR THE TREATMENT OF ACNE

Publications (1)

Publication Number Publication Date
AR002002A1 true AR002002A1 (en) 1998-01-07

Family

ID=46093359

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP950100314A AR002002A1 (en) 1994-11-25 1995-11-24 USE OF THE EPIDERMIC GROWTH FACTOR IN THE MANUFACTURE OF A MEDICINE IN THE FORM OF HYDROPHILIC CREAM FOR THE TREATMENT OF ACNE.

Country Status (3)

Country Link
AR (1) AR002002A1 (en)
CU (1) CU22613A1 (en)
WO (1) WO1996016669A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101725062B1 (en) * 2014-05-29 2017-04-10 주식회사 대웅제약 Pharmaceutical composition for preventing or treating skin rash

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0140998B1 (en) * 1983-11-02 1989-11-15 Nihon Chemical Research Kabushiki Kaisha Ophthalmic preparations
US5023090A (en) * 1989-08-16 1991-06-11 Levin Robert H Topical compositions containing LYCD and other topically active medicinal ingredients for the treatment of ACNE
CN1083371A (en) * 1993-01-03 1994-03-09 周至惠 Acne, folliculitis, erythra special nursing agent

Also Published As

Publication number Publication date
WO1996016669A1 (en) 1996-06-06
CU22613A1 (en) 2000-02-10

Similar Documents

Publication Publication Date Title
US4826830A (en) Topical application of glyciphosphoramide
US7300666B2 (en) Mixture for transdermal delivery of low and high molecular weight compounds
CA1338779C (en) Method for treating pain associated with herpes-zoster and post-herpetic neuralgia by topical application of local anesthetics
AR068816A1 (en) COMPOSITIONS OF BRIMONIDINE IMPROVED FOR THE TREATMENT OF ERYTHEMA
CN108135972B (en) Application of mussel mucin product in treating and preventing melanin-related diseases
US8409628B2 (en) Methods and compositions for oxygenation of skin to treat skin disorders
JP2009513506A (en) Use of osmolite obtained from extreme environmental bacteria for the manufacture of a medicament for the external treatment of neurodermatitis
CN101835495A (en) Use of conjugates of hyaluronic acid in the local treatment of hyperproliferative skin diseases
RU2008106932A (en) COMPOSITIONS FOR LOCAL USE CONTAINING O-DESMETHYLVENILAFAXIN (EFA) OR ITS SALTS
EP1684681B1 (en) A mixture for transdermal delivery of low and high molecular weight compounds
WO2016029328A1 (en) Pharmaceutical composition for preventing, treating, and curing psoriasis including snail slime, chamomile, and honey
AR002002A1 (en) USE OF THE EPIDERMIC GROWTH FACTOR IN THE MANUFACTURE OF A MEDICINE IN THE FORM OF HYDROPHILIC CREAM FOR THE TREATMENT OF ACNE.
AU7562091A (en) Compositions comprising cytotoxic agent and permeation enhancers
ES2692834B2 (en) MICROSPHERES FOR THE TREATMENT OF DISEASES OF THE SKIN OR DERMATOLOGICAL, OSTEOMUSCULAR AND VASCULAR
ES2292711T5 (en) FAVORING THE CELLULAR RECONSTRUCTION AND / OR THE CELL DIFFERENTIATION WITH NON METABOLIZABLE SUGAR AND A POLYMER ABSORBENT.
JP6656890B2 (en) Filaggrin production promoter
EP2810641A1 (en) Topical pharmaceutical and medical device preparations containing combinations of sucralfate, hyaluronic acid, arginine and a natural moisturizing agent
US9585962B1 (en) Treatment for actinic keratoses
Goh et al. Tuberculosis cutis in Singapore: a two year experience
ATE91079T1 (en) SALICYLIC ACID AGENT AGAINST SCALPING SKIN DISEASES.
HU207446B (en) Method for producing medicinal preparation of local use
TW202302628A (en) Derived peptides of lactoferrin and a use thereof for promoting and/or increasing lipid synthesis
US20220133677A1 (en) Topical composition
ITRM20130686A1 (en) NEW COMPOSITION FOR TOPICAL USE
BG112635A (en) Dosage form for local application